ALSO NOTED: Cancer vaccine market to soar; Point Therapeutics cuts staff; and much more...

> Analysts say that the cancer vaccine market will soar to $8 billion by 2012. Report

> Fledgling Point Therapeutics has cut its workforce by 15 percent, with most of the cuts focused on its preclinical development group. "In our ongoing efforts to further talabostat's clinical development, particularly our Phase III program, it became necessary for Point to undertake measures to reduce our costs," said CEO Don Kiepert. The company announced positive preclinical data on talabostat at the end of October. Release

> Australia's pSivida has inked a deal with an investment fund for $33.7 million in funds to advance its macular edema therapy. Report

> Dendreon is touting positive preliminary data from a new trial of Provenge that demonstrated its effect in boosting the immune response to fight prostate cancer. Almost half of the patients in the study benefited from the drug. Report

> The wrinkle treatment company Thermage raised $42 million in its IPO, significantly under its original expectations. Report

> Cambridge, MA-based Immunogen says its Phase I trial of its anticancer therapy huN901-DM1 shows it was well tolerated and produced evidence of efficacy that included a complete remission for one of the patients enrolled. Release

> Boehringer Ingelheim has received the FDA's approval to market Mirapex for restless leg syndrome. Mirapex has long been on the market as a therapy for Parkinson's symptoms. Release

> Alnylam has filed a shelf registration with the SEC to periodically sell up to $150 million in stock. Alnylam is focused on RNAi, a hot prospect in the biotech world. Report

And Finally… A new class of sirtuin activators are being pursued by biotechs who see big potential in the anti-aging therapies. Article

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.